NCT02953743
Pharmacokinetic Study of E7080/Lenvatinib in Chinese Patients With Unresectable Hepatocellular Carcinoma (HCC) treatment 1 completed NCT05967143
Observational SIR-Spheres Study for the Treatment of Unresectable Liver Tumors (SIRtain Registry) No drug interventions Not Available Not Available recruiting NCT05630937
Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable Hepatocellular Carcinoma (HCC) Previously Treated With Systemic Therapy No drug interventions treatment 1 / 2 completed NCT04175912
Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver treatment 2 active_not_recruiting NCT05667064
Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study No drug interventions Not Available Not Available recruiting NCT04770896
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab treatment 3 recruiting NCT06117891
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery Not Available Not Available recruiting NCT06503250
A Study of Participants With Initially Unresectable Hepatocellular Carcinoma That is Treated With Atezolizumab and Bevacizumab Plus Transarterial Chemoembolization Not Available Not Available recruiting NCT06590844
"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma treatment 4 active_not_recruiting NCT06593964
TACE With Thermosensitive Nanogel Versus Embosphere for HCC No drug interventions treatment Not Available recruiting NCT05135364
HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure treatment 2 recruiting NCT01015833
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer treatment 3 completed NCT05345678
Himalaya Early Access Program Not Available Not Available approved_for_marketing NCT05582278
HAIC+Lenvatinib+Tislelizumab vs D-TACE+Lenvatinib+Tislelizumab for Unresectable HCC treatment 2 recruiting NCT04605185
Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma treatment 1 active_not_recruiting NCT06360042
Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC treatment 2 recruiting NCT05660213
Effect and Safety of Huaier Granules Combined With Targeted Drugs and Anti-PD-(L)1 Antibody Compared With Targeted Drugs Combined With Anti-PD-(L)1 Antibody in First Line Treatment of Unresectable Hepatocellular Carcinoma(uHCC) treatment 4 not_yet_recruiting NCT01217034
Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib treatment 2 unknown_status NCT03107416
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells treatment 1 / 2 active_not_recruiting NCT05214339
A Trial of Hepatic Arterial Infusion Combined With Bevacizumab and Sintilimab for Unresectable A-staged Hepatocellular Carcinoma in BCLC Classification (D-TRIPLET) treatment 2 unknown_status NCT03345225
A Clinical Study of Precision TACE (P-TACE) With Surefire No drug interventions device_feasibility Not Available withdrawn NCT06485466
TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma treatment 3 recruiting NCT05286320
Phase Ib/II Trial of Combining Pembrolizumab and Lenvatinib With SBRT for HCC Patients With Portal Vein Thrombosis. treatment 1 / 2 not_yet_recruiting NCT05917431
Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC treatment 2 recruiting NCT05957640
Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma treatment 1 recruiting NCT02093104
TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) No drug interventions Not Available Not Available completed NCT05103904
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant treatment 2 recruiting NCT05269381
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors treatment 1 / 2 recruiting NCT04387695
SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT treatment 3 recruiting NCT05176223
68Ga PSMA PET Imaging for the Treatment of Advanced Liver Cancer treatment 2 recruiting NCT06310590
Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma treatment 1 recruiting NCT01556490
Efficacy Evaluation of TheraSphere in Patients With Inoperable Liver Cancer No drug interventions treatment Not Available completed NCT04736121
Selective Internal Radiation Therapy (SIRT) Using SIR-Spheres® Y-90 Resin Microspheres on DoR & ORR in Unresectable Hepatocellular Carcinoma Patients No drug interventions treatment Not Available active_not_recruiting NCT01900002
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery treatment 2 completed NCT04829383
A Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma treatment 2 active_not_recruiting NCT03942328
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer treatment 1 / 2 recruiting NCT01004978
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery treatment 3 completed NCT04947956
Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma Not Available Not Available not_yet_recruiting NCT05199285
A Phase II Study of Nivolumab + Ipilimumab in Advanced HCC Patients Who Have Progressed on First Line Atezolizumab + Bevacizumab treatment 2 recruiting NCT06496815
Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy treatment 4 not_yet_recruiting NCT05096715
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC treatment 1 recruiting NCT05507632
Donafenib Plus Sintilimab in Combination With TACE in Patients With Unresectable Hepatocellular Carcinoma treatment 2 not_yet_recruiting NCT04401800
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma treatment 2 completed NCT02989870
Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma treatment 1 withdrawn NCT06280313
Impact of Splenectomy on the Efficacy of Targeted Therapy and Immunotherapy in Unresectable HCC Patients With Cirrhotic Portal Hypertension No drug interventions Not Available Not Available recruiting NCT05263219
DEB-TACE+HAIC vs. HAIC for Large HCC No drug interventions treatment 3 recruiting NCT00988741
Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy treatment 2 completed NCT05168163
Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer treatment 2 recruiting NCT02006030
Ph 2 Trial of ADI PEG 20 Plus Concurrent Transarterial Chemoembolization (TACE) Vs TACE Alone in Patients With Unresectable Hepatocellular Carcinoma treatment 2 completed NCT00829465
Clinical Research of Licartin Combined With TACE in the Treatment of Unresectable Hepatocellular Carcinoma No drug interventions treatment 4 completed NCT04605731
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer treatment 1 recruiting NCT00247676
An International Phase 2 Study Of SU011248 In Patients With Inoperable Liver Cancer treatment 2 completed NCT06315101
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China Not Available Not Available completed NCT01176604
Yttrium Y 90 Glass Microspheres in Treating Patients With Unresectable Hepatocellular Carcinoma No drug interventions treatment Not Available completed NCT03896646
Radioembolization for HCC Patients With Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D) No drug interventions treatment Not Available active_not_recruiting NCT03695250
BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver Cancer treatment 1 / 2 terminated NCT05327738
Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma treatment 2 withdrawn